FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
London UK; Philadelphia US; Geneva, Switzerland - July 20, 2018 -- GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 21, 2018 Category: Drugs & Pharmacology Source Type: news

Swiss Rolls recalled over potential salmonella contamination
Flowers Foods calls back Swiss Rolls sold under numerous brand names, as well Captain John Derst's Old Fashioned Bread, due to possible salmonella contaminaition (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 20, 2018 Category: Consumer Health News Source Type: news

Swiss, German drugmakers join U.S. price freeze
Roche, Bayer and Germany's Merck KGaA became the latest drug companies to freeze prices in the United States, amid increased scrutiny by the Trump administration of medicine costs. (Source: Reuters: Health)
Source: Reuters: Health - July 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Radiation from smartphones could trigger memory loss in teenagers, new study reveals
Researchers from the Swiss Tropical and Public Health Institute studied nearly 700 adolescents between the ages of  12 and 17 in Switzerland (stock image). (Source: the Mail online | Health)
Source: the Mail online | Health - July 20, 2018 Category: Consumer Health News Source Type: news

Roche gets breakthrough status for Alzheimer's test Elecsys
The U.S. Food and Drug Administration has granted Roche an accelerated review for its Elecsys product used to diagnose Alzheimer's disease, the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - July 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Swiss regulators to overhaul export certification system
By Stewart Eisenhart, Emergo Group Swissmedic, Switzerland’s medical device market regulator, will replace its current processes for issuing export certificates as well as manufacturing certificates with an online system in order to prevent delays and free up resources. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees. The post Swiss regulators to overhaul export certification system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 19, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog Emergo Group Source Type: news

Roche takes Tecentriq hit on survival data
Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Reminder: Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call
Roche will publish its Half Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 26th July 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2018 Category: Pharmaceuticals Source Type: news

Roche still awaiting Tecentriq survival data in key study
Roche's Tecentric immunotherapy mixed with chemotherapy has not yet achieved a hoped-for overall survival target in first-line lung cancer treatment, the Swiss drugmaker said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug
Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mobile phone radiation may affect memory performance in adolescents
(Swiss Tropical and Public Health Institute) Radiofrequency electromagnetic fields may have adverse effects on the development of memory performance of specific brain regions exposed during mobile phone use. These are the findings of a study involving nearly 700 adolescents in Switzerland. The investigation, led by the Swiss Tropical and Public Health Institute (Swiss TPH), will be published on Thursday, July 19, 2018 in the peer-reviewed journal Environmental Health Perspectives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2018 Category: International Medicine & Public Health Source Type: news

Roche Touts New Flu Drug as Tamiflu Suffers Generics Hit Roche Touts New Flu Drug as Tamiflu Suffers Generics Hit
Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Novartis posts Q2 beat, promises to hold off on drug price hikes
Shares in Novartis (NYSE:NVS) were up today after the company beat expectations on Wall Street with its second-quarter financial results. The Switzerland-based company posted profits of $7.77 billion, or $3.34 per share, on sales of $13.16 billion for the three months ended June 30. Novartis saw its quarterly sales climb 7% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Novartis posts Q2 beat, promises to hold off on drug price hikes appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Novartis Source Type: news

Novartis shelves US price increases
Swiss pharma group’s move comes after Trump criticised rising costs in sector (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 18, 2018 Category: Pharmaceuticals Source Type: news

Polares Medical raises $25m
Preclinical Swiss medtech group Polares Medical said today it closed a $25 million funding round to support its mitral valve repair technologies. Funding in the round was led by Decheng Capital and joined by Endeavour Vision, IDO Investments, Earlybird Venture Capital and Wellington Partners, the company said. Polares Medical is developing a “hemi-replacement” solution for the mitral valve through which the posterior leaflet is replaced with a prosthetic leaflet designed to enhance coaptation with the native anterior leaflet. “Hemi-replacement represents a new treatment paradigm for mitral regurgitation, ...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Funding Roundup polaresmedical Source Type: news

Reva lands new partner in Italy for bioresorbable scaffold
Reva Medical (ASX:RVA) said today that it inked a deal with Bio Vascular Group to distribute Reva’s Fantom bioresorbable scaffold in Italy. The partnership expands Reva’s commercial activities to Italy, adding to its ongoing efforts in Germany, Switzerland, Austria and Turkey. Get the full story at our sister site, Drug Delivery Business News. The post Reva lands new partner in Italy for bioresorbable scaffold appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Vascular Wall Street Beat Reva Medical Inc. Source Type: news

Roche touts new flu drug as Tamiflu suffers generics hit
Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche lauds new flu drug trial as Tamiflu suffers generics hit
Swiss drugmaker Roche's hopes of regaining ground in the influenza market have been boosted after a late-stage study showed its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche nabs trial win for investigational anti-viral flu drug
Roche said on Tuesday its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications from flu, a boost to the Swiss drugmaker's efforts to win approval for the single-dose, oral anti-viral medicine. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Democrats allege Trump lawyer had broad contacts with Novartis
Swiss pharmaceutical company sought ‘access to key policymakers’ after 2016 election (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 13, 2018 Category: Pharmaceuticals Source Type: news

Verbal and non-verbal aggression in a Swiss university emergency room: a descriptive study - Kaeser D, Guerra R, Keidar O, Lanz U, Moses M, Kobel C, Exadaktylos AK, Ricklin ME.
Workplace violence (WPV) by patients and visitors is a hazard in many emergency departments (ED), with serious consequences for both staff and patients. Patients with a migratory background seem to be prone to being involved in WPV. We therefore reviewed a... (Source: SafetyLit)
Source: SafetyLit - July 12, 2018 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Gerresheimer to acquire Sensile Medical and its drug-delivery tech
Gerresheimer plans to acquire Swiss medical technology company Sensile Medical and its array of liquid drug delivery devices. The buyout is a perfect fit in Gerresheimer’s portfolio, the company explained, since it will boost Gerresheimer’s drug delivery offerings and add new digital and electronic capabilities into the mix. Get the full story at our sister site, Drug Delivery Business News. The post Gerresheimer to acquire Sensile Medical and its drug-delivery tech appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Mergers & Acquisitions Pharmaceuticals gerresheimer Sensile Medical AG Source Type: news

FDA Advisory Committee Endorses the Effectiveness and Safety of Single-Dose Tafenoquine for the Radical Cure of P. vivax Malaria
London UK; Philadelphia US; Geneva, Switzerland - 12 July 2018 - GSK and Medicines for Malaria Venture (MMV) today announced that the Antimicrobial Drugs Advisory Committee (AMDAC) of the United States Food and Drug Administration (FDA) voted that... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 12, 2018 Category: Drugs & Pharmacology Source Type: news

Once with lofty plans, Novartis now closing East Bay unit, cutting 140 jobs
Novartis AG will shutter its infectious diseases unit, closing an operation it moved from the Boston area to Emeryville seven years ago and cutting about 140 jobs. The Switzerland-based company (NYSE: NVS) told employees Wednesday that it will shut down antibacterial and antiviral research — a move that affects a number of related work, such as pharmacology, protein sciences and informatics — while retaining the 150 employees who make up a tropical dise ases unit the company moved a year ago… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 12, 2018 Category: American Health Authors: Ron Leuty Source Type: news

Once with lofty plans, Novartis now closing East Bay unit, cutting 140 jobs
Novartis AG will shutter its infectious diseases unit, closing an operation it moved from the Boston area to Emeryville seven years ago and cutting about 140 jobs. The Switzerland-based company (NYSE: NVS) told employees Wednesday that it will shut down antibacterial and antiviral research — a move that affects a number of related work, such as pharmacology, protein sciences and informatics — while retaining the 150 employees who make up a tropical dise ases unit the company moved a year ago… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 11, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Hospital disaster preparedness in Switzerland over a decade: a national survey - Dell'Era S, Hugli O, Dami F.
OBJECTIVE: The present study aimed to provide a comprehensive assessment of Swiss hospital disaster preparedness in 2016 compared with the 2006 data. METHODS: A questionnaire was addressed in 2016 to all heads responsible for Swiss emergency depart... (Source: SafetyLit)
Source: SafetyLit - July 10, 2018 Category: International Medicine & Public Health Tags: Disaster Preparedness Source Type: news

Medication practices and experiences of older adults discharged home from hospital: a feasibility study protocol - Roux P, Pereira F, Santiago-Delefosse M, Verloo H.
BACKGROUND: Switzerland's aging population raises pressing questions about maintaining older adults in their home environments and the problems associated with managing complex treatments requiring medication in such contexts. Few studies have examined old... (Source: SafetyLit)
Source: SafetyLit - July 6, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Molecule combos show promise against autoinflammatory diseases
Two small molecule combinations have shown potential for treating autoinflammatory diseases in a recent study in Switzerland. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 5, 2018 Category: Consumer Health News Source Type: news

Culturally shared metaphors expand contemporary concepts of resilience and post-traumatic growth: contrasting an indigenous Brazilian community and a Swiss rural community - Meili I, Heim E, Maercker A.
The metaphorical concepts resilience and post-traumatic growth (PTG) reflect the contemporary Western understanding of overcoming highly challenging life events. However, it is known that across different cultures, a broad range of metaphoric... (Source: SafetyLit)
Source: SafetyLit - July 5, 2018 Category: International Medicine & Public Health Tags: Disaster Preparedness Source Type: news

Switzerland weighs relaxing marijuana ban
ZURICH (Reuters) - Switzerland, which permits low potency cannabis but bans most marijuana for recreational use, aims to allow pilot studies on ways to relax its laws, its government said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - July 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Switzerland weighs relaxing marijuana ban
Switzerland, which permits low potency cannabis but bans most marijuana for recreational use, aims to allow pilot studies on ways to relax its laws, its government said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - July 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche 'highly encouraged' by Tecentriq results in breast cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

There is no such thing as a 'normal' vagina, scientists conclude in the largest study ever of vulvas
Swiss researchers measured the vulvas of 650 white women aged 15 to 84. There was so much variety that they concluded even an 'average' would woefully misrepresent most women. (Source: the Mail online | Health)
Source: the Mail online | Health - June 29, 2018 Category: Consumer Health News Source Type: news

Novartis: one in the eye
Foresight has not been the Swiss drug manufacturer’s forte (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - June 29, 2018 Category: Pharmaceuticals Source Type: news

Novartis and Alcon to Separate
Novartis said it plans to spin out its Alcon Division into a separately-traded company. The move will allow the Basel, Switzerland-based company and Alcon to focus on respective growth strategies. If the split meets general market conditions, regulatory approvals, final Board of Directors endorsement, and shareholder approval then the planned separation could be completed by the first half of 2019. Novartis said if the Alcon spin out is completed, then it would create a new Switzerland-based company with global scale and reach comprising more than 20,000 employees, with around $7 billion in 2017 sales. The firm said that i...
Source: MDDI - June 29, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Novartis to spin out Alcon ophthalmic subsidiary
Novartis (NYSE:NVS) said today that it’s planning to spin its Alcon ophthalmology subsidiary into a publicly traded company after years of speculation that it wanted to sell the ill-starred division. The Swiss pharma giant said it intends to hold on to Alcon’s $4.6 billion ophthalmic pharmaceuticals business under the Novartis Innovative Medicines umbrella, continuing a transition begun in January 2016. If consummated as expected during the first half of 2019, the separation of the remaining the surgical and vision care business would create a $7 billion enterprise with more than 20,000 employees, Novartis said...
Source: Mass Device - June 29, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Optical/Ophthalmic Pharmaceuticals Wall Street Beat Alcon Novartis Source Type: news

Rival Novartis, Gilead CAR-T therapies win European panel recommendation
Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within a couple of months. (Source: Reuters: Health)
Source: Reuters: Health - June 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis slims down with $25bn spin-off of Alcon eyecare business
Swiss drugmaker’s new chief Vas Narasimhan refocuses on core medicines (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - June 29, 2018 Category: Pharmaceuticals Source Type: news

Sensile, Sanofi, and Verily Form Diabetes Dream Team
There has been a lot of movement in the diabetes space lately – especially with the 78th Scientific Sessions of the American Diabetes Association ending earlier this week. One of the latest developments in the diabetes space is a “dream team” collaboration with Sensile Medical, Sanofi and Verily (formerly Google Life Sciences) to develop a connected insulin patch pump. Olten, Switzerland-based Sensile Medical develops devices for liquid drug delivery. The three parties said they will develop and commercialize a new generation of “all-in-one” pre-filled insulin patch pump, primarily to ser...
Source: MDDI - June 28, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news

Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call
Roche will publish its Half Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 26th July 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - June 28, 2018 Category: Pharmaceuticals Source Type: news

Neutrality: a tool or a limit for preventing mass atrocitiy crimes and genocide? The case of Switzerland - Persoz G.
The present article aims to confront the Swiss practice regarding the prevention of genocide and mass atrocities in Swiss foreign policy and its particularities shaping its international relations. Neutrality, a core part of Switzerland's identity on both ... (Source: SafetyLit)
Source: SafetyLit - June 28, 2018 Category: International Medicine & Public Health Tags: Jurisprudence, Laws, Legislation, Policies, Rules Source Type: news

FDA gives one-dose flu drug priority review
A one-dose flu drug that kills the virus in a day has been granted priority review by the U.S Food and Drug Administration. Manufacturer Genentech said approval for the drug, baloxavir marboxil, also known as Xofluza, could come by the end of the year, NBC News reports.   The drug was co-developed by Japanese pharmaceutical company Shionogi& Co. and Swiss healthcare company Roche Holding AG (OTC:RHHBF), which owns Genentech. Genentech obtained commercial rights to Xofluza outside of Japan and … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 27, 2018 Category: American Health Authors: Anne Stych Source Type: news

Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump
Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Get the full story at our sister site, Drug Delivery Business News. The post Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 27, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Sanofi-Aventis Sensile Medical AG Verily Source Type: news

Functional assessment and injury risk in a professional soccer team - G ómez-Piqueras P, González-Víllora S, Sainz de Baranda Andújar MDP, Contreras-Jordán OR.
At the last World Conference on Sport and Physical Therapy celebrated in Bern (Switzerland, 2015), it was confirmed that the functional skills of an athlete are a very important variable to be considered in the recovery of an injury. On the other hand, its... (Source: SafetyLit)
Source: SafetyLit - June 27, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Taking one's own life in hospital? Patients and health care professionals vis- à-vis the tension between assisted suicide and suicide prevention in Switzerland - Reiter-Theil S, Wetterauer C, Frei IA.
In Switzerland, the practice of lay right-to-die societies (RTDS) organizing assisted suicide (AS) is tolerated by the state. Patient counseling and accompaniment into the dying process is overtaken by RTDS lay members, while the role of physicians may be ... (Source: SafetyLit)
Source: SafetyLit - June 26, 2018 Category: International Medicine & Public Health Tags: Commentary Source Type: news

Which fall ascertainment method captures most falls in pre-frail and frail seniors? - Teister CJ, Chocano-Bedoya PO, Orav EJ, Dawson-Hughes B, Meyer U, Meyer OW, Freystaetter G, Gagesch M, Rizzoli R, Egli A, Theiler R, Kanis JA, Bischoff-Ferrari HA.
There is no consensus on most reliable falls ascertainment method. Therefore, we investigated which method captures most falls among pre-frail and frail seniors from two randomized controlled trials conducted in Zurich, Switzerland, a 18-month trial (2009-... (Source: SafetyLit)
Source: SafetyLit - June 26, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Stryker to acquire Swiss surgical smoke firm SafeAir
Stryker (NYSE:SYK) said yesterday that it agreed to acquire Swiss surgical smoke evacuation firm SafeAir for an undisclosed amount. Root, Switzerland-based SafeAir’s “smoke pen” device is a disposable diathermy pencil with an integrated smoke evacuation function that connects with a smoke evacuator to pull the smoke from cauterization procedures directly from its source. Surgical smoke conveys roughly the same mutagenic and carcinogenic risks as cigarette smoke, plus the risk that it could carry bacteria or virus cells and damage the respiratory tract and the lungs. “The acquisition of SafeAir ...
Source: Mass Device - June 26, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Surgical Wall Street Beat SafeAir Stryker Source Type: news

Trial from Niger finds village-wide prophylactic antibiotics contained spread of meningitis
(PLOS) Distribution of single doses of the oral antibiotic ciprofloxacin to residents of rural villages in the African meningitis belt reduced the number of meningitis cases during a 2017 meningitis epidemic, according to a new study in PLOS Medicine by Matthew Coldiron and colleagues from Epicentre and M é decins Sans Fronti è res in France, Switzerland and Niger. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 26, 2018 Category: Infectious Diseases Source Type: news

Study Preserves Hopes for Roche's Tecentriq in Lung Cancer Study Preserves Hopes for Roche's Tecentriq in Lung Cancer
Swiss drugmaker Roche's hopes of having the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form of lung cancer remained intact on Monday after a trial showed positive survival data.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Man's throat started to ROT after he swallowed bleach causing him to spend 2 weeks in intensive care
A 65-year-old man in Switzerland went to hospital after swallowing a bleach tablet by accident, thinking it was paracetamol. He spent two weeks in intensive care but made a recovery. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2018 Category: Consumer Health News Source Type: news